Redeye retains its positive view on Speqta, currently trading below net cash. We leave our Base Case unchanged, awaiting the revised strategy and management’s capital allocation plans.
ANNONS
Redeye retains its positive view on Speqta, currently trading below net cash. We leave our Base Case unchanged, awaiting the revised strategy and management’s capital allocation plans.